Skip to the issue
ISSUE ONE
01

The Next
Evolution Review

Technology  ·  Ethics  ·  Human Purpose   |   October–November 2026
The issue

The distance between proven and permitted

A naval trial put a new atomic clock to sea on one programme's authority. A brain scanner built from related physics has been in research use since 2021 and is still waiting for approval. Twelve cases, one question: who holds the authority to say yes?

Cover story  ·  page
Count the signatures first
Health & care  ·  page
The scan that works in the study, and the route that runs out
Design & measurement  ·  page
The one case where permission was forced, and the gain went wider
NEIL CATTON  ·  INDEPENDENT TECHNOLOGY STRATEGIST
NEILCATTON.COM
Issue One · October–November 2026

What this is, and how to read it

The Next Evolution publishes several times a week. That cadence has a cost: an argument that takes six pieces to build is never visible in any one of them. Every two months the Review takes one question, sets a substantive piece against it, and gathers the writing that approaches the question from other directions.

Nothing here is a reprint. Where an argument first appeared in shorter form on the Substack, the fact box at the foot of the article names the original.

Reading it

The findings are on page and the cover story on page . Each article opens with a three-line summary and closes with a fact box.

On the evidence

Factual claims carry numbered source notes in each article's fact box, pointing to the primary source. Judgements are marked as judgements. Where the evidence stops, the text says so. How the cases were chosen, how verdicts and confidence are assigned, and what the author declares are set out on page .

Published by

Neil Catton
Independent technology strategist. Fractional CTO and CIO work, board briefings, AI readiness reviews, technology due diligence and programme recovery.

Books

The Next Evolution
The Cognitive Crucible
The Shadow System
Working as Designed

Where to find the writing

writing.neilcatton.com
neilcatton.com

Version

Version 1.0, October 2026. Later revisions are dated here and listed on the corrections page.

Cite as

Catton, N. (2026). The distance between proven and permitted. The Next Evolution Review, Issue 1, October–November 2026.

Reuse

Quote it, cite it, send it on. Attribution is the only condition.

The question this issue is built on

When something that works does not reach the people it was built for, how many people had to say yes, and who is answerable for the time they took?

Contents · Issue One

The distance between proven and permitted

In briefFive findings, one page
The issue at a glanceSix cases, who has to agree before each can reach people, and where the sections fit
EditorialThe pattern was in the archive before it was in my head
Cover story  ·  The distance between proven and permittedSix cases side by side, and three where the argument fails
Reference
Three shapes of a permission chainShort, long and absent, with the remedy each one takes
Health & care technology
The scan that works in the studyA brain-MRI reader validated at scale, and the route it now has to travel
The bottleneck movedDiscovery in eighteen months, proof still measured in years
Science & emerging technology
The material that was never on the formConcrete that repairs itself, and a specification that cannot see it
Two technologies nobody is blockingSmall modular reactors and precision farming
Governance & accountability
Nobody owns the delayRegisters price the risk of acting and leave the cost of waiting unrecorded
The permission that was never going to be givenConsultation as a record of having asked
Security & cybercrime
They already have itThe standards were published in 2024. The first milestone is discovery
When the postcode decides your protectionDefence distributed by employer rather than by need
Human agency & attention
Permanent, portable, wrongThe permission nobody was asked for, and the record that cannot be corrected
Design & measurement
The standard that raised the barPermission forced, and a gain wider than the group it was written for
Standing pages
Corrections, second thoughts and callsWhere the writing was wrong, and dated calls to be scored in later issues
Method, sources and declarationsHow cases were chosen, how verdicts and confidence are assigned
The archive on this questionThe published pieces the arguments were built from
What this issue foundThe ledger of every case, and five questions to take away
Issue Two The question, and how it was chosen
In brief

Five findings

Each finding names the page where the evidence is.

1
Where a working technology stalls, count the people who must agree before blaming the technology.
Ten of the twelve cases are graded. The number of authorities that must agree explains the delay in two and partly explains it in two more. The naval clock in the cover story needed one authority and went to sea; the brain scanner beside it needs four and has been in research use since 2021.
Evidence: cover story, page · ledger, page
2
The hardest chain to see is the one where nobody is asked.
A maintenance saving that arrives forty years after the decision, as with self-healing concrete, has no line on the tender that could score it. No one refuses the material. The fix is a place on the form for that saving.
Evidence: page · reference diagram, page
3
Governance prices the risk of acting and records nothing about the cost of waiting.
A deferral is minuted as caution, and nobody owns what it costs. Each body in a chain can explain its own timetable; nobody is asked for the total.
Evidence: page
4
The argument fails where the product is unproven or the problem is price.
Three cases are not explained by permission at all: small modular reactors, precision farming, and cyber protection that is bought rather than provided.
Evidence: pages and
5
In three cases permission runs the other way, and the person carrying the cost has no say.
Data profiles are built without anyone's agreement, public consultation asks for views it cannot act on, and encrypted records are collected now to be read later while the decision to protect them waits inside the organisation.
Evidence: pages , and
What to do with it

Five questions for any stalled technology are on page .

The issue at a glance

Six technologies, and who has to agree

Each row is one case from the cover story. Each square is an authority that must agree before the technology can reach people.

must agree can act still to come never asked Status and calls, right
Optical atomic clock, naval trial Royal Navy uncrewed test submarine, 2025
1✓
Trialled 2025
OPM-MEG brain scanner Research use since 2021
1234?
Waiting Approval hoped 2027 · C1
AI reading of brain MRI Validated 2026; not in routine care
1234?
Ahead A forecast
AI-discovered lung drug Target to candidate in about 18 months
123?
Relocated Phase III from July 2026 · C2
Self-healing concrete Full-scale tests from 2011
———
Never asked No line on the tender
Small modular reactors A counter-case
EngineeringUnit cost
Not permission First unit late · C3
Fig. 1  Authorities that must agree, per case, September 2026. Status is sourced in the cover story's fact box; the count is the author's reading of each route. C1–C3 are dated calls, page .

Where the sections fit

Health & care technology
The longest chains, each approval added after a real failure
The scan that works in the study
The bottleneck moved
Science & emerging technology
One case the count explains, two it does not
The material that was never on the form
Two technologies nobody is blocking
Governance & accountability
Why nobody adds up the delay
Nobody owns the delay
The permission that was never going to be given
Security & cybercrime
A decision that waits inside the organisation, and protection sold by price
They already have it
When the postcode decides your protection
Human agency & attention
A record built without anyone's agreement
Permanent, portable, wrong
Design & measurement
A requirement imposed over objection, and a wider gain
The standard that raised the bar
Editorial

The pattern was in the archive
before it was in my head

Four times between July and September I wrote a version of the same article without noticing. In July it was self-healing concrete, which has been through full-scale trials since 2011 and is still absent from most specifications. Later that month it was software that reads brain scans in seconds, validated on tens of thousands of real studies and still some distance from routine care. In August it was a drug for a fatal lung disease, taken from target to candidate in eighteen months and then handed to a trial system that runs at the speed it always has. In September it was an optical atomic clock that went to sea on a naval test submarine, set against a brain scanner that shares its physics, in research use since 2021 and still waiting for approval.

I noticed on the fourth. The record I keep of published work flagged the overlap and asked what separated the new piece from three older ones. I did not have a good answer, which is usually the sign that something needs writing.

The answer, when it came, was that I had written one argument four times, in twelve hundred words each, which is too little room to make it. Each piece could show that the technology worked and an institution stood in the way. None could ask why the obstruction takes the shape it does, or what would have to change for it not to.

That is why this exists.

What a periodical is for

A newsletter suits one idea at a time. It suits an argument that needs six examples, two counter-examples and a structural claim underneath them far less well, because by the fourth example the reader has had three emails across five weeks and no reason to hold them together.

A periodical has room for it, and it imposes a discipline a stream does not: you decide in advance what the next two months are about. That decision is most of the value. The writing between issues gets aimed, and an argument gets built on purpose rather than assembled afterwards from whatever happened to appear.

The question

When something that demonstrably works fails to reach the people it was meant for, we tend to call the problem adoption, or funding, or culture, or readiness. Those words point at the receiving institution and suggest it should try harder. In several of the cases here, the delay is the sum of decisions taken by several bodies.

Somebody, or more often a set of somebodies, has to say yes. The useful question is how many separate people must agree, whether any of them is answerable for the consequence of not deciding, and what happens to the person waiting while they take their time.

Count the signatures. It is a simple test, and it explains more of what I have written this year than I expected. The diagrams and the ledger that follow are there to test it, including against the cases where it fails.

What I am not claiming

One version of this argument says the technology is always ready and institutions are always the problem. I do not hold it, and three of the twelve cases here do not support it at all. Small modular reactors are held up by engineering and cost. Precision farming was designed for a farm most farmers do not have. Cyber protection is deployed and working, and reaches people according to who employs them.

The argument holds only where the thing works. Telling those cases apart from the others is most of the work, which is why the ledger at the back grades the cases and publishes the ones where the argument fails.

How this issue is built

Each piece is summarised in three lines at its head and sourced at its foot. The cases come from my own writing rather than a survey, and the method page says what that means for the conclusions. The corrections page already has one entry.

The last page carries the question Issue Two is built on. It was chosen the same way this one was, by looking at what I kept writing without meaning to.

Cover story · Issue One

The distance between
proven and permitted

Six technologies that work, or are said to. Some have reached people and some are waiting. The science separates them less than the number of bodies that must agree, none of which answers for the time taken.
The case
Six technologies, from a naval clock to self-repairing concrete, set side by side.
The claim
Where something works and still does not arrive, count the authorities that must agree before blaming the technology.
Who carries the cost
Patients, asset owners and others outside the decision, who have no say in it.

Two machines rest on related physics. One is an optical atomic clock. In 2025 it went to sea aboard XCal, the Royal Navy's uncrewed test submarine, in a trial of navigation that does not depend on satellites.1 The other is a brain scanner. Its sensors, optically pumped magnetometers, came out of work to make atomic clocks smaller, and they read the brain's faint magnetic fields from a helmet a child can wear while moving.2 A system of this kind was installed in a paediatric epilepsy diagnostic suite in 2021.3 In July 2026 the researchers behind the technology said it is still not used clinically, because it needs medical device approval, which they hope to have in 2027.2

These are different devices, so the comparison is limited to one point: how each was allowed to be tried. The navy tested its clock at sea, on an operational testbed, on the authority of the programme that runs the submarine. The scanner can be used in research with children who have epilepsy, but it cannot inform a clinical decision about them until a regulator certifies it. After that it needs an assessment of whether the evidence justifies the cost, a commissioning route that decides whether it is bought, and a trust budget that decides whether it is bought here.

Each of those four bodies exists for a sound reason, and each has to agree before the next one acts.

The claim

Where a technology works and still does not reach people, the obstruction is usually how many bodies must agree. Ask how many there are, and whether any of them pays a price for taking its time.

Three more cases

Concrete that repairs itself

Self-healing concrete, in full-scale tests since 20114 and now sold commercially,5 is rarely specified. Public tenders are scored mainly on the cost of building, so a lower maintenance bill forty years later has nowhere to be counted, even though government guidance asks for whole-life costing.6 Page sets out the mechanism.

Software that reads a brain scan

A University of Michigan model that reads brain MRIs, validated in 2026 on more than 30,000 real studies,7 is not yet in routine care. Its route through the NHS runs through the same four bodies as the scanner, and nobody publishes how long the four take together. This case is still a forecast (page ).

A drug found in eighteen months

Insilico Medicine found rentosertib, a drug for idiopathic pulmonary fibrosis, and took it from target to preclinical candidate in about eighteen months;8 a phase III trial began in China in July 2026.9 Formal medicines regulation in the UK dates from the response to thalidomide in the 1960s,12 and the trial system is slow on purpose. Faster discovery has moved the wait from the laboratory to the clinic, where the people waiting know the drug's name (page ).

Who must say yes

One

A single programme holding the budget, the mandate and the risk. The naval clock trial.

Who must say yes

Four

Regulator, evidence assessor, commissioner, local budget holder. The scanner, and the MRI reader behind it.

Who must say yes

Nobody

The saving arrives decades after the decision and has no line on the tender. The concrete.

Fig. 3  Three shapes of a permission chain. Author's classification.

Three cases the count does not explain

Small modular reactors are held back by engineering and unit cost. China's Linglong One, the first land-based commercial unit, was due to begin commercial operation in May 2025 and had not been confirmed as operating by early October 2026.10 Precision farming has been taken up more slowly than its dealers forecast for twenty-five years,11 because it was built for large, uniform farms. Cyber protection works and is widely deployed, and small organisations go without it because of price. Pages and take these in turn.

Six cases, one table

CaseStatus, September 2026What is holding itShape
Optical atomic clock, naval trialTrialled at sea, 20251Nothing further for a trial. One programme, one authority.Short
OPM-MEG brain scannerResearch use since 2021; approval hoped for 20272,3Device approval first, then three more authorities.Long
Self-healing concreteFull-scale tests from 2011; on the market4,5A tender scored on build price.Absent
AI reading of brain MRIValidated at one health system, 2026; not in routine care7The four approvals ahead of it.Long, ahead
AI-discovered lung drugPhase III from July 20268,9Trial and approval, deliberately slow.Relocated
Small modular reactorsFirst commercial unit behind schedule10Engineering and unit economics.Not permission
Fig. 4  Status columns are sourced (see notes). The Shape column is the author's argument.

Why nobody fixes it

Each body in these chains was added for a reason. Medical devices and medicines are regulated because unregulated ones harmed people, and the UK's own review of that history reads as a list of specific injuries.12 An evidence body exists because health systems bought expensive things that did not work. A local budget holder exists because central decisions did not fit local conditions.

What none of them records is the length of the whole. A risk register records what happens if a decision goes wrong: financial exposure, regulatory breach, reputational damage, safety. It has no entry for what happens if the decision is not made this quarter. A committee that defers is minuted as cautious. A committee that approves and is wrong is minuted as having failed.

So the delay has no owner. Everyone in the chain asks for the evidence their own remit requires, and the total belongs to none of them.

What gets measured

The risk of yes

Financial exposure. Regulatory breach. Clinical safety. Reputation. Each appears on a register, has an owner, and is reviewed on a cycle.

What does not

The cost of not yet

The scans not read. The maintenance bill in 2060. The diagnosis that arrived late. None has an owner, a register entry or a review date.

Fig. 5  What governance records and what it leaves out. Author's judgement.

Who waits

In each case the person who waits is outside the room. Whoever maintains a bridge in thirty years is not consulted on its specification. Whoever needs a scan in a district general hospital is not represented at the commissioning meeting. Whoever has the lung disease is not a party to the trial protocol. None of them can see the process that is making them wait.

A count on paper

Adding a new approval step to fix a slow chain would lengthen it. What is proposed here is smaller. For any technology that works and has not reached people, write down how many separate bodies must agree, what each is protecting, and whether any has been asked what the delay costs. At present the only figure anyone produces is the risk of moving, and the cost of standing still is treated as zero. The five questions on page set this out.

Where this leaves it

The navy put its clock to sea on the authority of one programme. The scanner has been in research use for five years and is waiting on the first of four approvals. Both systems are working as designed. Which of the four bodies is answerable for the five years?

Fact box  ·  Sources for the cover story
  1. Infleqtion, "Infleqtion and Royal Navy demonstrate world's first quantum optical clock on underwater autonomous submarine", October 2025. infleqtion.com
  2. Wellcome, "OPM-MEG: a revolution in brain imaging technology", 7 July 2026. wellcome.org
  3. UCL News, "Wearable brain scanner to facilitate testing for children with epilepsy", October 2021. ucl.ac.uk
  4. Ingenia, "Self-healing concrete", March 2011 (announces full-scale outdoor testing from 2011). ingenia.org.uk
  5. NWO, "Self-healing concrete", November 2021 (Basilisk products on the market). nwo.nl
  6. Cabinet Office, The Construction Playbook, version 1.1, September 2022 (whole-life value and should-cost models). gov.uk
  7. Michigan Medicine, "An AI model that can read and diagnose a brain MRI in seconds", February 2026; published in Nature Biomedical Engineering. michiganmedicine.org
  8. Ren F. et al., "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models", Nature Biotechnology, online 8 March 2024.
  9. Insilico Medicine, Nature Medicine phase IIa publication, June 2025; phase III initiation, 7 July 2026. insilico.com
  10. NucNet, SMR database entry for ACP100 (Linglong One), accessed September 2026. smr.nucnet.org; World Nuclear News, 8 January 2026.
  11. Malone T., Fiechter C. et al., "Is precision agriculture technology adoption persistently overestimated?", Agribusiness, 2026. doi:10.1002/agr.70085
  12. Independent Medicines and Medical Devices Safety Review (Cumberlege), Annex H, "History of regulation", 2020. immdsreview.org.uk
Fuller piecesThe same physics, two speeds (7 Sep 2026) · The Science Is Not the Problem (13 Jul) · While patients wait (26 Jul) · The bottleneck moved (17 Aug) · Too Cheap to Meter, Too Slow to Build (6 Jul) · The Land the Data Missed (5 Aug). writing.neilcatton.com
Reference · Cover story

Three shapes of a permission chain

Chains obstruct in three ways, and each needs a different remedy.

01
Short
One authority holds the budget, the mandate and the risk. A decision can be taken and acted on without a second signature.
Decide Act
In this issue: the optical atomic clock trialled aboard the Royal Navy's uncrewed test submarine.
Remedy: none needed for speed. Whether that concentration of authority is acceptable is a separate question.
02
Long
Four or more authorities, each answering a legitimate question, none able to act alone, all able to wait. Each was added after a specific harm.
Certify Assess Commission Fund Act
In this issue: the OPM-MEG brain scanner, in research use since 2021 and awaiting approval; the brain-MRI reader validated in 2026.
Remedy: record the total, so the sum of four reasonable requests has an owner and a date. Every link stays.
03
Absent
No authority is involved, and the technology still does not arrive. The saving lands outside the remit of anyone deciding, so the question never reaches anybody.
Not asked Not scored Not reached
In this issue: self-healing concrete, tested full-scale from 2011 and still rare in specifications.
Remedy: give the form a place for the value it cannot currently record, and name who speaks for it.
Fig. 6  Three shapes of a permission chain. Author's classification; the cases are sourced in the cover story's fact box.
Before applying any of this

Establish that the thing works

Has it performed, in conditions like service, for somebody other than its makers? Small modular reactors and precision farming for the typical farm fail that test (page ), and for them the shapes above are beside the point.

Section one

Health & care technology

Health has more separate bodies that must agree than any other sector here, each added after something went wrong. Two pieces: software validated at scale that now faces that chain, and a drug found quickly that must still be proved slowly.

Health & care · One

The scan that works in the study

Software that reads a brain MRI in seconds has been validated on more than 30,000 real studies. When it reaches a district general hospital depends on four approvals, and nobody knows how long they take together.
The case
A brain-MRI reader validated at one US academic health system in 2026.
The claim
Validation starts the permission chain. Four NHS approvals lie ahead, and nobody publishes how long they take together.
Who carries the cost
Patients far from the specialist centres that adopt first, who already wait longest.

A brain scan taken in a district general hospital joins a queue, and a radiologist works through the queue. The number of trained people, and how long each image takes, sets the pace for everything behind it.

In February 2026 researchers at the University of Michigan published a model, Prima, which interprets a brain MRI within seconds. It was trained on more than 200,000 past studies and tested on more than 30,000 over a year, with accuracy of up to 97.5% across more than fifty diagnoses.1 It is not yet in routine clinical care.

Four approvals, each with a reason

Software that informs a diagnosis has to be certified as a medical device. That requirement exists because unregulated devices caused harm; the UK's review of medicines and device safety sets out how each layer of regulation followed a specific failure.2

It then has to be assessed for whether the evidence justifies the cost, because a health system with a fixed budget that buys things which do not work is taking money from things that do. It then needs a commissioning route: somebody has to decide that this is something the service buys, under which tariff, counted how. Finally an individual trust, with its own budget and its own list of pressures, has to decide that this is what the money goes on this year.

Each of the four is run by people acting reasonably. The likely result is that the capability reaches teaching hospitals first, where research budgets and academic partnerships can absorb the early cost, and reaches everywhere else over a period nobody has estimated in public.

A word to drop

Adoption

The word implies an institution choosing not to take something up. Here nobody refuses; four bodies each ask for what their remit requires, and nobody adds up the total.

Who waits

NHS England's own waiting-list breakdowns show that patients in the poorest communities are more likely than any other group to wait longer than 18 weeks for treatment.3 They are also the people least able to travel to a hospital that has a new capability, take time off for an appointment two counties away, or pay to go private while they wait.

A diagnosis that arrives late is often a different diagnosis. Described as a productivity tool, the software's slow rollout is a missed saving. Described as a change in who gets diagnosed in time, it decides which patients benefit first, and nobody records that decision.

How long

I have found no published figure for the average time between a diagnostic technology being validated at scale and being available across the service. The regulator can state its own timescales, and so can the evidence assessor and the commissioner. No single body is responsible for the total, which is probably why nobody has published one.

Simpler things meet the same problem. At a health innovation showcase, a medical student presented a single kit for a particular procedure. They had watched clinical teams finish that procedure and then account for every item used, and sometimes fail to. The kit released each stage only once the previous stage's components had been used, and finished as one sealed, disposable container. When I asked afterwards how deployment was going, the answer was that it was not: procurement raised one blocker, clinical teams another, and there was no single route into practice.

A record of the chain

One document per technology would be enough: the bodies that must agree, the question each is answering, the evidence each has asked for, and the date of each request, kept where a board would see it. It would put names and dates against a wait that currently belongs to nobody.

Fact box
The casePrima, a brain-MRI model from the University of Michigan (2026)
Status, Sept 2026Validated on 30,000+ studies; not in routine clinical care
Who decides nextDevice regulator, evidence assessor, commissioner, trust budget holder
VerdictPartly explains  Confidence: low. The delay is a forecast.
Sources
  1. Michigan Medicine, "An AI model that can read and diagnose a brain MRI in seconds", February 2026; Nature Biomedical Engineering.
  2. Independent Medicines and Medical Devices Safety Review, Annex H, "History of regulation", 2020.
  3. NHS England, "NHS publishes waiting list breakdowns to tackle health inequalities", July 2025. england.nhs.uk
Fuller piece

While patients wait, 26 July 2026 · The same physics, two speeds, 7 September 2026. writing.neilcatton.com

Health & care · Two

The bottleneck moved

An AI-driven programme took a candidate drug for a fatal lung disease from target to candidate in about eighteen months. The trials that must prove it works still take years.
The case
Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, now in phase III.
The claim
Faster discovery without faster proof moves the wait to the clinic. The slowness of proof is deliberate and mostly right.
Who carries the cost
People with a named disease who now know a named compound exists.

Insilico Medicine took rentosertib, a candidate for idiopathic pulmonary fibrosis, from target discovery to preclinical candidate in roughly eighteen months.1 The company puts conventional early-stage discovery at two and a half to four years.2

What did not change is everything after discovery. A candidate has to be shown to be safe, then shown to work in people against a comparator at a scale that makes the result mean something, then accepted by a regulator. Rentosertib reported phase IIa results in Nature Medicine in June 2025, and a phase III trial across 47 centres in China began in July 2026.2 None of those stages has been compressed, and nobody has seriously proposed compressing them.

The same pattern turns up well outside medicine. In one part of UK local government, I watched contact centres move residents onto digital channels. Requests arrived faster and in greater volume, but the teams who had to act on them had the same number of people as before. Waiting times did not improve; the backlog grew further down the line.

Slow on purpose

In the UK, a Committee on Safety of Drugs was set up in 1963 in response to thalidomide, and the Medicines Act 1968 followed; the regulation of medical devices developed separately and later.3 Pharmaceutical regulation is, more than almost any body of rules, a record of specific disasters. Approval on weaker evidence would mean accepting the risk of repeating one of them.

The position

The trial system should not be sped up

Accelerating one half of a two-stage process still has a consequence. The total wait did not shorten; it moved to a place where the person waiting knows the drug exists.

Waiting for a named drug

Before, a person with a fatal lung disease was waiting for something that had not been found. Now the same person is waiting for a named compound, in a trial with a protocol and a timetable, which may or may not include them depending on their stage and where they live. They can search for the drug by name and read eligibility criteria that may exclude them.

A wait with a visible end is experienced differently from one without, and trial teams now deal with patients who know exactly what they are waiting for. Nothing in the regulatory process was designed with that in mind.

Where the pressure will land

It will land on the trial system, as demand for expanded access, compassionate use, adaptive protocols and other routes that let somebody take a drug before the evidence is complete. Some of those routes are sound and some lead back towards the failures regulation exists to prevent. Telling them apart will be one of the main regulatory questions of the next few years, and it will be decided under pressure from people with a named disease.

What counting shows here

There are many signatures in this chain and each is doing its job, so counting them will not shorten the wait. What the count does show is a change in the problem. The delay used to be one part of a mostly scientific problem, and now it is most of what remains.

Fact box
The caseRentosertib (ISM001-055), Insilico Medicine, for idiopathic pulmonary fibrosis
Status, Sept 2026Phase III began July 2026 (China, 47 centres)
Who decides nextTrial outcome, then medicines regulators
VerdictPartly explains  Confidence: moderate.
Sources
  1. Ren F. et al., Nature Biotechnology, online 8 March 2024 ("roughly 18 months from target discovery to preclinical candidate nomination").
  2. Insilico Medicine, phase IIa publication announcement, June 2025; phase III initiation, 7 July 2026. insilico.com
  3. Independent Medicines and Medical Devices Safety Review, Annex H, "History of regulation", 2020.
Fuller piece

The bottleneck moved, 17 August 2026 · The Machine That Designs Medicines, 19 April 2026. writing.neilcatton.com

Section two

Science & emerging technology

Self-healing concrete, where counting the signatures explains the delay, and two technologies where it explains nothing.

Science & emerging technology · One

The material that was never on the form

Concrete that seals its own cracks has been tested in full-scale structures since 2011 and is on the market. It rarely appears in specifications, and nobody has had to turn it down.
The case
Bacteria-based self-healing concrete, developed at TU Delft and now on the market.
The claim
A permission chain can obstruct with no links at all, when the benefit falls outside every decision-maker's scope.
Who carries the cost
Whoever holds the asset decades later and pays for its maintenance.

The mechanism sounds invented. Bacteria are mixed into the concrete in a dormant state, along with a nutrient. When a crack opens and water gets in, the bacteria wake, feed, and produce limestone that fills the crack from inside.

Full-scale outdoor testing began in 2011,1 and Basilisk, the spin-out that grew from the Delft work, has taken self-healing products to market.2 The engineering is understood, and the material still appears in few specifications.

No one says no

Construction procurement is decided on the price of building the thing. That is what the tender is scored on and what the person deciding is accountable for. Self-healing concrete costs more to lay. Over a long maintenance life it can cost less in total, because the repairs it avoids are expensive and disruptive. But the maintenance budget decades from now is not a line on today's tender, so a material that may be cheaper overall is scored as dearer, and it rarely wins.

The third shape

A missing field

Here the chain has no links and still obstructs. There is no refusal to appeal, only a form with no place to record the saving.

Whole-life costing exists, and rarely wins

Government guidance already asks for this. The Construction Playbook tells public buyers to focus on whole-life value and to build should-cost models of whole-life costs.3 The pattern persists anyway.

Whole-life costing asks the person scoring a tender to estimate costs over a period longer than their tenure, the political cycle and the warranty. It needs assumptions about discount rates, usage, climate and maintenance, each arguable and each likely to be argued by a losing bidder. A scorer who relies on build price is easy to defend. One who relies on a forty-year projection is exposed.

In the public-sector bids I have written and responded to as a consultant, questions about whole-life cost beyond the contract term have been rare. The contract length sets the horizon: it is the only period a bidder can answer for, because what happens after may be delivered by someone else. The buyer seldom asks either, so neither side is accountable for the cost that arrives later.

Who pays

The maintenance cost does not vanish. It passes, in full, to whoever holds the asset in twenty, thirty and forty years, often a public body with a maintenance backlog it did not create. The person who takes the decision and the body that pays for it may never deal with each other.

The question for a procurement

A saving that arrives after the decision-maker has gone, falls to another organisation, or cannot be shown without a projection someone could attack never gets weighed at all. So ask of any procurement who must sign, what kinds of value the tender can record, and who in the process speaks for the maintenance budget in 2060.

Fact box
The caseBacteria-based self-healing concrete (TU Delft; Basilisk)
Status, Sept 2026Commercially available; rarely specified
Who decidesTender scorers, on build price
VerdictExplains  Confidence: low. No source measures why it is rarely specified; the reason given is the author's reading.
Sources
  1. Ingenia, "Self-healing concrete", March 2011. ingenia.org.uk
  2. NWO, "Self-healing concrete", November 2021. nwo.nl
  3. Cabinet Office, The Construction Playbook, version 1.1, September 2022. gov.uk
Fuller piece

The Science Is Not the Problem, 13 July 2026 · Good Enough for Now, 25 June 2026. writing.neilcatton.com

Science & emerging technology · Two

Two technologies nobody is blocking

Small modular reactors are behind schedule and unproven at commercial scale. Precision farming was built for the wrong farm. Neither is a permission problem.
The case
Small modular reactors, and precision agriculture.
The claim
Where a technology is unproven, or designed for the wrong user, counting signatures avoids the real question.
Who carries the cost
Whoever funds the subsidy, and the farmers the tools were not built for.

Say that working technologies are held up by institutional permission, and the claim is useful at once to anyone selling something that does not work yet and would prefer nobody checked.

Small modular reactors are the clearest current example. The promise is to build reactors in a factory, standardise the design and bring the cost down through volume. If it worked it would matter a great deal, because the options for firm low-carbon power at scale are few and all difficult.

What has been delivered

The first land-based commercial unit, China's Linglong One, was planned to enter commercial operation in May 2025. In January 2026 the target was reported as the first half of 2026,1 and at the start of October I could find no confirmation that it had begun. The cost case depends on manufacturing volumes that cannot exist until enough units are ordered to justify the factory, while the orders depend on the costs, which depend on the volumes. Nobody has yet shown how to break that circle.

None of this makes the technology fraudulent. It is unproven in the sense that matters commercially: the thing the whole case rests on has not yet been shown.

Before counting

Is it proven?

Counting signatures helps only where a technology already works for people other than those who built it. Where that has not been shown, start there.

Regulatory delay is real, and secondary

Nuclear regulation is slow and evidence-heavy, and a regime designed around one-off gigawatt plants may fit a repeated factory-built unit badly. Reforming it is a legitimate policy question, and a separate one from what is holding these reactors back. If every design in the queue were approved tomorrow, the first units would still face the engineering, supply-chain and first-of-a-kind problems that no regulator creates. Blaming the regulator moves a commercial problem into politics.

Built for another farm

For twenty-five years, the dealers who sell precision agriculture have overestimated how widely farmers would take it up. A 2026 study of the Purdue dealership survey, covering 26 technologies from 2000 to 2025, found the overestimation persistent, and widening in the early 2020s as adoption of several tools flattened.2

The instruments work. They were designed for a large, uniform, well-capitalised farm, and most farms are not like that. No regulator stood in the way. The product was wrong for most of the people it was sold to.

I once represented the UK at a European committee discussing a proposed personal “passport” for lifelong learning: one record of a person's qualifications, certifications, work history and references, which any employer could see with permission. The aim was to make moving and hiring people across Europe far simpler. It returned to the committee each year and never progressed beyond discussion. As far as I could see, it had been designed around employers and institutions, with little thought for how an individual would ever use it.

How to tell the cases apart

Ask whether the thing has worked, in conditions like those it would meet in service, for someone other than the people who built it. Self-healing concrete passes. The brain scanner passes in research use. Small modular reactors do not yet pass, and neither does precision farming for the typical farm.

The first question to ask of any stalled technology is whether it is any good, asked by someone with no stake in the answer. By the time a technology reaches an approval process, that question has often been skipped.

Fact box
The casesSmall modular reactors; precision agriculture
Status, Sept 2026First commercial SMR behind schedule; precision-ag adoption below dealer forecasts
What holds themEngineering and unit economics; design fit
VerdictDoes not explain  Confidence: moderate. The delays are sourced; their causes are the author's reading.
Sources
  1. NucNet, SMR database entry for ACP100 (Linglong One), accessed September 2026. smr.nucnet.org; World Nuclear News, "Chinese SMR completes non-nuclear steam start-up test", 8 January 2026.
  2. Malone T., Fiechter C. et al., "Is precision agriculture technology adoption persistently overestimated?", Agribusiness, 2026. doi:10.1002/agr.70085
Fuller piece

Too Cheap to Meter, Too Slow to Build, 6 July 2026 · The Land the Data Missed, 5 August 2026. writing.neilcatton.com

Section three

Governance & accountability

Registers price the risk of acting and record nothing about the cost of waiting. The second piece looks at a process built to produce a record rather than a decision.

Governance & accountability · One

Nobody owns the delay

A board can usually state the risk of approving something. It is rarely asked what the quarter it spent deciding cost, or who paid.
The case
The risk register, and the decisions it leaves unrecorded.
The claim
Deferral is a decision that is never minuted as one, so the cost of waiting has no owner.
Who carries the cost
People outside the organisation, who wait while it decides.

Look at what a risk register contains: financial exposure, regulatory breach, operational failure, reputational damage, safety. Each entry has an owner, a score, a mitigation and a review date, and the discipline behind it is real. A well-kept register is one of the more useful tools in corporate governance.

Now look for the entry that records what it costs the organisation, or anyone else, if a decision is taken in March instead of January. The standard categories have no place for it.

I was once responsible for part of the reporting to a risk and audit committee. The same report came back each month with its dates moved further out, and nobody asked what the delay was costing the organisation or might cost later. I inherited some of the consequences: deferred decisions that had become problems of their own. The cost was the work stopped or postponed to deal with them, and nobody measured it.

The asymmetry

This follows from how accountability is built. A committee that approves something which then fails has made an identifiable decision with an identifiable outcome: a minute, a date, a set of names. The failure attaches. A committee that defers, asks for more evidence or refers the matter elsewhere has also decided, but it reads as diligence. If the deferral cost something, the cost is diffuse, arrives later and usually falls on someone outside the organisation.

So the two options are unequal, and nobody in the chain has to be timid or self-interested for the whole to run slow. Everyone can act in good faith and the outcome is still set by the shape of the accountability.

The structural point

Deferral goes unrecorded as a decision

Approving carries a named owner and a reviewable outcome. Waiting carries neither, so the register tilts every close call towards waiting.

Every department did its job

There is a failure pattern in which every part of an organisation does its job correctly and the outcome is still wrong, because the gap that produced it was on nobody's map. Delay is the clearest example. The regulator answers a regulatory question in the time its process takes. The evidence body answers an evidence question, the commissioner a commissioning question, the trust a budget question. Every authority in a chain can account for its own timescale. None is asked for the sum.

Asking each body to go faster leaves the total unowned. Making the total somebody's responsibility is harder, because the aggregate crosses the boundary of every organisation involved, and there is no obvious candidate.

One sentence in the minute

The usual answer to a governance gap is a new governance artefact, which usually lengthens the chain. A narrower step would not: for any decision a board defers, record beside the deferral what exactly is being waited for, and what the delay costs and to whom.

Most of the time the cost will be small and the pause sensible, and writing that down takes a minute. The value is in the cases where the answer is uncomfortable, where writing it down turns a diffuse condition into a decision with an author.

Whether it would change outcomes is untested. The present arrangement, in which the risk of acting is quantified and the cost of waiting is not recorded at all, has rarely been examined as a choice. Would your board know what its last deferral cost, and who paid?

Fact box
The pieceArgument about governance mechanism; not graded as a case
EvidenceAuthor's judgement. No external figures are cited.
VerdictProposes the mechanism the ledger tests
Sources

No external sources: this piece is argument.

Fuller piece

Every Department Did Its Job, 1 May 2026 · The Board That Didn't Understand What It Had Approved, 10 June 2026 · It can be managed, 17 July 2026. writing.neilcatton.com

Governance & accountability · Two

The permission that was never going to be given

Consultation looks like a permission chain. Often it is a process built to produce a defensible record of having asked, and the people being asked have noticed.
The case
Public consultation as a stage that must be run, and that no answer moves.
The claim
Where one link in a chain is ceremonial, the chain is slow and also dishonest, and it drives away the people with the most useful knowledge.
Who carries the cost
Individuals with direct experience, who stop responding.

A consultation that draws few responses leaves the body running it with a convenient explanation: apathy. Apathy belongs to the public rather than the process, and it implies the remedy is better communication.

A more likely reason is that nothing changed. Most consultations are run politely, and responses are read, coded and summarised in an annex. But where the decision has already been made, and the consultation is the stage that has to be completed before it can be announced, people can tell, and giving up is a rational response.

I have responded to local consultations where the framing of the questions made it clear the decision had already been made, and I responded anyway on the points I thought needed challenging. On one proposal to build a large warehouse, the published results showed only a handful of responses from a community of thousands who had been asked. A number like that tells people responding is pointless, and the decision then goes through by default because almost nobody objected.

What the process is for

A consultation has to be run before some decisions can be taken. If it is not run, the decision can be challenged. If it is run and the record shows responses were received and considered, the decision is defensible. The process is therefore tuned to produce the record, and change is optional.

You can see it in the design. Questions are often framed after the options have been narrowed. The timetable is often set by something else. The way a response could change the outcome, as distinct from being noted, is seldom written down.

A test

Ask what would have to be said to change the answer

A consultation that can name the response that would alter the decision is still open. One that cannot is collecting a record.

A signature that cannot say no

In most of the cases in this issue someone waits for permission that could be given. Consultation is a stage that is real and visible and cannot change the result, so each signature also has to be attached to a decision that could go either way. A chain of four live decisions is slow. A chain of three live decisions and one ceremonial one is slow and dishonest, and the dishonest link makes people outside less willing to engage with the other three.

The cost that is never counted

Consultations that change nothing compound. Each one reduces the number of people who will respond to the next, until the response comes mainly from those with a professional reason to reply: trade bodies, campaign groups, organisations with a paid policy function. The individual with direct experience, whose account is the most useful and available nowhere else, has left. The body running the process rarely notices, because response rates are watched in total and their make-up is not.

Saying which kind it is

There are two legitimate processes. One says: this decision is taken, we are telling you first, here is how to prepare. The other says: this decision is open, here is what could change it, and here is who decides. The damage comes from running the first while describing it as the second.

Fact box
The casePublic consultation as a stage of permission
EvidenceAuthor's judgement from published pieces; no external figures cited
VerdictRuns the other way  Confidence: low. No external evidence is cited; this is argument.
Sources

No external sources: this piece is argument.

Fuller piece

The consultation that changed nothing, 26 June 2026 · The Feedback Loop That Actually Worked, 31 July 2026. writing.neilcatton.com

Section four

Security & cybercrime

The standards exist, the milestones are published and the work is understood, and the decision still waits, because the harm sits in the future and the cost sits in this year's budget. The second piece is a case permission does not explain.

Security & cybercrime · One

They already have it

Encrypted data can be collected now and read later. The replacement standards were published in August 2024, and the UK's first migration milestone is simply to find out what cryptography you run.
The case
Migration to post-quantum cryptography in UK organisations.
The claim
When the decision is internal and the harm is deferred, the yes goes ungiven for the same reason a register never records the cost of waiting.
Who carries the cost
Anyone whose long-lived records are being collected today.

An adversary who copies encrypted traffic today cannot read it. The copy costs little to keep, and the bet is that one day the mathematics protecting it will give way. Then all of it can be read at once, including what was sensitive when it was sent and still is.

For a well-resourced actor this is cheap against the possible return, and the prudent assumption is that it is happening to anything worth collecting.

The replacement standards, cryptography designed to survive a quantum computer, were published by the US National Institute of Standards and Technology in August 2024.1 In March 2025 the UK's National Cyber Security Centre set out milestones: by 2028, define goals and complete discovery and assessment; by 2031, carry out the highest-priority migrations; by 2035, complete migration.2

In the sectors I work with, much of the data being held matters for decades: health records, insurance policies, mortgages, criminal convictions. The conversations I have about protecting it tend to be about current encryption and current standards. I have rarely heard anyone ask how they are preparing for post-quantum encryption.

Why the decision waits

No regulator is withholding approval here and no commissioner is failing to find a route. The decision sits inside the organisation and can be taken by people already in the building.

It goes untaken because of how the harm is shaped. The cost of migration is large, immediate and lands in a named budget. The harm it prevents is uncertain in timing, falls in some later year, and will be felt by whoever holds the role then. A finance director weighing that against eleven other calls on the same money is reading the incentives in front of them accurately, and deferring is a reasonable response to them.

The shape of the problem

Cost now, harm later

A breach that migration prevents will never be credited to the migration, because an attack that does not happen leaves no evidence.

Discovery is the first milestone

The NCSC is explicit that migration starts with understanding your current estate: identifying key services and applications, and recording the data you hold, how long it needs to stay confidential, and its value to an adversary.2 That work is comparatively cheap and useful for other purposes.

It also puts the exposure on record. Once the estate is understood, deferral becomes a documented acceptance of a specific risk. Some reluctance to start is about capacity. Some of it is that not knowing is more comfortable, and current governance rewards the comfort.

Where the human consequence sits

Much of what is worth storing for a decade is about people: medical records, legal matters, communications, financial histories, casework of every kind. A person whose records are collected today cannot know it and cannot withdraw them. They carry the risk, and nobody at the budget meeting where migration is deferred another year speaks for them.

When

Nobody can say when the mathematics gives way, and credible estimates vary widely. That uncertainty is often offered as a reason to wait. It is a better reason to start, because the collecting is happening now whatever the date turns out to be, and the NCSC's own timetable runs to 2035.

Fact box
The casePost-quantum cryptography migration
Status, Sept 2026Standards final (2024); UK milestones 2028 / 2031 / 2035
Who decidesThe organisation itself, usually its finance and risk owners
VerdictRuns the other way  Confidence: moderate. Standards and milestones are sourced; the reason for deferral is the author's reading.
Sources
  1. NIST, "NIST releases first 3 finalized post-quantum encryption standards" (FIPS 203, 204, 205), August 2024. nist.gov
  2. National Cyber Security Centre, "Timelines for migration to post-quantum cryptography", 20 March 2025. ncsc.gov.uk
Fuller piece

They Already Have It, 20 July 2026 · The Error is the Point, 24 May 2026. writing.neilcatton.com

Security & cybercrime · Two

When the postcode decides your protection

The defences that catch fraud and phishing before they reach anyone are bought, and scaled to the organisation paying for them. The self-employed face the same kinds of attack without them.
The case
Cyber protection for sole traders, micro-businesses and the self-employed.
The claim
The technology works and is deployed at scale. It is distributed by ability to pay, which is a different problem from permission.
Who carries the cost
The smallest organisations, which face the same common attacks with the least protection.

A small business I know of found fraud on one of its accounts. After a lot of investigation of their own, the owners traced it to an old account nobody used any more and closed it, by which time the criminals had moved into other systems. Sorting it out with the banks and other institutions took weeks. Spotting it, reporting it, responding and locking everything down afterwards were all left to them.

Inside a large company, monitoring might have flagged the dormant account, detection might have noticed the unusual activity, and a response team could have acted within the hour. That protection is bought, and its quality tracks what the organisation spends. Whether a given person in this country is protected against the most common digital crime depends heavily on who employs them.

The population without it

The government's own survey found that 43% of UK businesses had a cyber security breach or attack in the preceding year, and that phishing was by far the most common, reported by 38% of businesses.1 The same survey finds formal cyber measures, from risk assessments to insurance, becoming less common the smaller the organisation.1 Sole traders, freelancers, small charities and single-handed practices meet the most common attack largely on their own.

The advice available to them is technically correct and of little practical use: check the sender, look for the signs, do not click the link. It hands the whole burden of defence to the least-resourced party and calls it personal responsibility, at a time when attacks are good enough to catch trained staff inside protected environments.

What is being asked

Do by hand, alone, what enterprises do with systems

Security guidance for individuals is a description of what enterprise security systems do, rewritten as instructions for a person who is also trying to run a business.

A market outcome

Nobody here is waiting for a regulator. The technology works, it is sold commercially and it is deployed at scale. The market has settled who gets it, by ability to pay rather than by exposure to harm. Counting signatures explains nothing, and the ledger records that.

That is a legitimate way to distribute many things. It is an odd way to distribute protection against crime, which is otherwise treated as something provided regardless of means. Nobody decided that digital crime should be the exception. It happened because the defence turned out to be a product rather than a service.

When it fails

A large organisation that is defrauded has a recovery function, lawyers, an insurer and a relationship with its bank. A sole trader has a customer services line and a burden of proof. The party least protected at the start is also least equipped to recover, and the recovery process was built around institutional liability.

So protection against a common crime is distributed by employer, and the people with the most exposure per pound of turnover carry it alone. Who, if anyone, should provide that protection for the smallest businesses?

Fact box
The caseCyber protection for the smallest organisations
Status, Sept 2026Protection deployed at scale; distributed by ability to pay
Who decidesThe market
VerdictDoes not explain  Confidence: high. The survey figures are direct.
Sources
  1. Department for Science, Innovation and Technology, Cyber security breaches survey 2025/2026, published 30 April 2026. gov.uk
Fuller piece

When the postcode decides your protection, 3 September 2026 · It Cannot Automate Trust, 8 May 2026. writing.neilcatton.com

Section five

Human agency & attention

Here nobody is waiting for a yes. The yes was taken without being asked for, and there is no practical way to withdraw it.

Human agency & attention · One

Permanent, portable, wrong

A record of what someone did becomes a description of who they are, follows them into credit, hiring and insurance decisions, and resists correction because every entry in it is accurate.
The case
Data profiles assembled from behaviour and sold on to decision-makers.
The claim
Permission runs backwards: several bodies must agree before a person gets a helpful scan, and none before a harmful record is built.
Who carries the cost
The person the record describes, who may never know it exists.

Consider Sam, who paid three bills late during a year of illness and spent several evenings searching about the condition. Sam's profile holds a record of lateness and a record of searching. It does not hold the illness, because the circumstance was never collected.

The profile was assembled by parties Sam never dealt with and is held for purposes Sam was not told about. Described that way it sounds like a scandal. Described the way the industry describes it, it sounds like an enrichment layer, which is one reason the debate has gone nowhere.

The deeper problem is a category error built into the design. A trace of behaviour records what someone did in a particular set of circumstances. A profile treats it as a description of what someone is, which does not follow.

Where it is used

These records travel. They feed credit decisions, employment screening, insurance pricing, tenancy referencing and a widening set of automated assessments in which the organisation has bought a score rather than looked at a person. The person assessed is not usually told which score was used, by whom, or on what basis, and the organisation using it often could not explain the basis either, because the score arrived as a product with a proprietary method.

Recruitment is where I see the risk most clearly. A gap in a career history, or several moves in a few years, is an accurate record, yet it is often read as a warning, and the candidate has to explain what was personal, or a redundancy. As AI tools take over more of the first sift of CVs, that reading risks being automated: a system that has learned what a conventional career looks like can treat a gap as an anomaly, with none of the context.

The design assumption

Built for the processor

Every part of the design serves the organisation consuming the profile: portability, coverage, ease of integration. Nothing serves the person it describes, including any route to see it or contest it.

Chains around benefits, almost none around harms

In health, four bodies must agree before a person can have a scan that might help them. Here, nobody has to agree before a record is built about them. What stands between a person and a permanent, portable record of their worst year is a consent notice on a website they visited once.

Why correction struggles

UK law gives people a right to have inaccurate personal data rectified.1 The regulator's own guidance explains why that right reaches less far than it sounds. A record of a mistake that has since been resolved is, in itself, accurate and should be kept, with the correction added; and a recorded opinion is hard to show to be inaccurate at all.1 Most profile entries are accurate traces used to support an inference. You cannot correct an accurate fact that is being used to prop up a conclusion it does not support.

Where this leaves Sam

With a record Sam cannot see, held by parties Sam cannot name, used in decisions Sam is not told about, and correct in every particular. Each decision is defensible alone. The damage comes from the accumulation, which has no owner. What would Sam need to know, and from whom, to contest any of it?

Fact box
The caseCommercial data profiles used in consequential decisions
Status, Sept 2026Widespread; right to rectification limited to inaccuracy
Who decidesNobody is asked
VerdictRuns the other way  Confidence: moderate. The legal position is sourced; how profiles are used is the author's reading.
Sources
  1. Information Commissioner's Office, "Right to rectification", UK GDPR guidance. ico.org.uk
Fuller piece

Permanent, Portable, Wrong, 8 July 2026 · The Decision Nobody Made, 16 April 2026. writing.neilcatton.com

Section six

Design & measurement

The one case here where a permission chain was overridden on purpose. The population that gained was much wider than the one the rule was written for.

Design & measurement · One

The standard that raised the bar

Accessibility requirements feel like a burden to the people who must meet them. The improvements they force often reach far more people than the group they were written for.
The case
Accessibility requirements: dropped kerbs, and subtitles.
The claim
When a requirement removes an assumption about the user, the benefit tends to spread. The wider gain never appears in the impact assessment.
Who carries the cost
Most people, some of the time.

A dropped kerb was cut for wheelchair users. It is used by anyone with a pushchair, a suitcase, a delivery trolley or a bad knee. The pattern is well enough known to have a name, the curb-cut effect, set out by Angela Glover Blackwell in 2017: changes made for one group that turn out to benefit many.1

Subtitles are the clearest measured example in the UK. In 2013 Ofcom reported that around 7.6 million UK adults said they had used television subtitles, of whom about 1.4 million had a hearing impairment.2 A service built for deaf and hard-of-hearing viewers was used, on those figures, mainly by people who were neither.

I worked on learning platforms for children where every part had to be usable by every child. One requirement was a choice of ways to log in, matched to different physical and cognitive abilities. Those options were built for children with particular needs. They also meant that no child had to remember a complex username and password.

Why it works this way

Designing for someone at the edge of what a system can accommodate forces you to drop assumptions that were never true for anyone: that the user has both hands free, full attention, good light and a quiet room. Most people are at that edge some of the time. The permanent condition of a small group is the temporary condition of a large one.

So a standard written for a minority often raises the floor for everyone rather than adding a feature for a few.

The finding

The compliance cost is counted and the wider benefit is not

Accessibility requirements arrive with a cost estimate and a lobby to argue it. The gain to people outside the target group falls outside the assessment's boundary, so nobody weighs it.

A chain that was overridden

Here a rule was imposed on organisations that would not have chosen it, over their objection, with a compliance date. That makes it the strongest evidence for a claim I am otherwise wary of: that the scoring is wrong as well as slow. Had the wider benefit been counted at the point of decision, the requirement would have looked like an improvement and would not have needed forcing.

It went uncounted for the same reason as the lifecycle saving on self-healing concrete. The benefit goes to people who are not the subject of the rule, in circumstances nobody anticipated, after the assessment was signed.

The limit

Not every imposed standard produces a wider benefit. Plenty are badly drafted, expensive, and deliver what they were narrowly written for and nothing more. The curb-cut effect is a repeated pattern with exceptions, and it would make a poor general case for regulation.

A narrower claim holds up. When a requirement forces the removal of an assumption about the user, rather than the addition of a feature for a group, the benefit tends to spread. That distinction is available whenever a standard is drafted, and it could be used to decide which standards are worth the cost.

Fact box
The caseAccessibility requirements: dropped kerbs and television subtitles
StatusEstablished; the wider benefit is documented
Who decidedLegislators and regulators, over objection
VerdictComparison: it arrived  Shown for contrast; not graded.
Sources
  1. Blackwell A. G., "The curb-cut effect", Stanford Social Innovation Review, Winter 2017. ssir.org
  2. Ofcom, "Improving the quality of live TV subtitles", press release, 20 May 2013.
Fuller piece

The Standard That Raised the Bar, 19 August 2026 · The Question That Changed the Design, 25 May 2026. writing.neilcatton.com

Standing page

Corrections, second thoughts and calls

Where earlier writing was wrong, where a position has moved, and dated calls to be scored later. This page appears in every issue, including when it is empty.

Correction  ·  The same physics, two speeds (7 September 2026)

What went to sea, and how fast

The piece described atomic sensing proving itself on a Royal Navy submarine within months. The sources support a narrower statement. The device was an optical atomic clock, trialled on XCal, an uncrewed Royal Navy test submarine, and announced by its maker in October 2025. The brain scanner's sensors grew out of atomic-clock components, so the physics is related rather than identical. The time from decision to naval trial could not be confirmed. This issue states the case accordingly.

Second thought  ·  on repetition

Four articles that turned out to be one

Between July and September four pieces made versions of the same argument without the repetition being recognised until the fourth. The response at the time was to sharpen each piece against the others. The better response was to give the argument room in one place. Recorded because the instinct to differentiate rather than consolidate is likely to recur.

Calls

Dated, specific and checkable. Each gives a likelihood in words and as a rough percentage, and a confidence of high, moderate or low (defined on page ). Each call is scored in the first issue after its date, right or wrong.

No.CallLikelihoodConfidence
C1An OPM-MEG brain scanner receives UK medical device approval for clinical use by 31 December 2027. Basis: researchers hope for approval in 2027 (Wellcome, July 2026).About even
(about 45%)
Low
C2Rentosertib is approved for idiopathic pulmonary fibrosis by any national medicines regulator by 31 December 2028. Basis: phase III began July 2026.Unlikely
(about 30%)
Moderate
C3Linglong One enters commercial operation by 31 December 2026. Basis: target moved from May 2025 to the first half of 2026; no confirmed start found at 2 October 2026.Likely
(about 65%)
Low
How to send a correction

If something here is wrong, say so. Corrections are published in the next issue with the reader credited unless they ask otherwise, and the original is amended with a dated note.

Standing page

Method, sources and declarations

How this issue was made, so a reader can judge what its conclusions rest on.

How the cases were chosen

The twelve cases come from the author's own published writing, mainly between July and September 2026, chosen because each bears on the question. Cases where the argument fails were included on purpose and are graded as failures. This is an argument built from cases rather than a survey or a sample, and the counts in the ledger describe the cases chosen, not how often anything happens in the world.

Sources

Factual claims carry numbered notes to the primary source in each article's fact box, checked in September 2026; the status of Linglong One was checked again on 2 October 2026. Where a figure comes from a company describing its own product, the note names the company. Judgements are labelled in figure captions and fact boxes, and the Shape and Verdict columns are the author's argument, not findings from the sources.

Verdicts

Ten cases are graded against one question: does counting the authorities that must agree explain why the technology has not reached people as it could? Two cases that did reach people, the naval clock and accessibility requirements, are shown for comparison and not graded.

ExplainsThe thing works, and the number and shape of the permission chain accounts for the delay.
Partly explainsPermission is part of the delay, but another constraint weighs as much, or the delay is still a forecast.
Runs the other wayPermission is present but works in reverse: the yes is internal, ceremonial, or never asked for.
Does not explainThe constraint is the product, the engineering or the price, not permission.
ComparisonThe technology reached people. Shown to contrast with the graded cases.

Likelihood and confidence

Calls state a likelihood as a plain word with an approximate percentage: unlikely (about 30%), about even (about 45%), likely (about 65%). Confidence is stated separately. High: the judgement rests mainly on direct, sourced evidence. Moderate: the facts are sourced and the cause is the author's reading. Low: a forecast, or an argument with little external evidence.

Declarations

The author works as an independent technology strategist. Current engagements include advisory work in UK public safety and policing data, in public-sector procurement, and with early-stage technology companies, one of them in insurance. Earlier consulting work included writing and responding to public-sector bids. This issue touches public-sector procurement (cover story; section two), public-sector governance (section three) and the protection of long-lived personal data (section four). The issue was not commissioned or paid for by anyone.

AI assistance

This issue was drafted with the assistance of Anthropic's Claude, working from the author's published writing and under his editorial direction. Sources were checked against the originals. Final responsibility for every argument and claim rests with the author.

Data and versions

The ledger and the calls are published as data (CSV) with the web edition. Version 1.0, October 2026. Revisions are dated in the imprint and listed on the corrections page.

The archive on this question

Published pieces that carry the theme further

Nothing in this issue is a reprint. These are the shorter pieces the arguments were built from, in order of publication, for a reader who wants the original.

The Last Person in the Queue
9 April 2026 · Health & social care
When digital becomes the default, the people who cannot use it become invisible to a system that stopped accounting for them.
The Questions Nobody Asks in the Room
10 April 2026 · Governance
The questions that would reveal whether a technology serves people are asked too late to change the decision.
What the Pilot Was Never Designed to Find
30 April 2026 · Governance
A pilot proves the technology works in the conditions designed for the pilot, and no further.
Every Department Did Its Job
1 May 2026 · Governance
When every part works and the outcome is still wrong, the gap is on nobody's map.
The Board That Didn't Understand What It Had Approved
10 June 2026 · Governance
Board governance was built for financial risk; AI-assisted decisions carry a different kind.
The consultation that changed nothing
26 June 2026 · Governance
Consultation often produces a defensible record of having asked, and communities have worked this out.
Too Cheap to Meter, Too Slow to Build
6 July 2026 · Science & emerging technology
The factory-model promise behind small modular reactors is plausible and commercially unproven.
Permanent, Portable, Wrong
8 July 2026 · Human agency
Profiles treat a behaviour trace as an identity and offer no real route to correction.
The Science Is Not the Problem
13 July 2026 · Science & emerging technology
Self-healing concrete meets a procurement system that scores the price of building.
They Already Have It
20 July 2026 · Security
Encrypted data is being collected against the day it can be read.
While patients wait
26 July 2026 · Science & emerging technology
AI that reads brain MRIs works at clinical scale in testing; funding and regulation govern the pace of deployment.
The Land the Data Missed
5 August 2026 · Science & emerging technology
Precision farming was designed for a farm most farmers do not have.
The bottleneck moved
17 August 2026 · Science & emerging technology
Discovery got faster; the system that proves a drug works did not.
The Standard That Raised the Bar
19 August 2026 · Design
Requirements written for excluded users raise the floor for everyone.
When the postcode decides your protection
3 September 2026 · Security
Cyber protection is distributed by employer rather than by need.
The same physics, two speeds
7 September 2026 · Science & emerging technology
A naval trial and a brain scanner, and who holds the authority to say yes. See the correction on page .
All pieces at writing.neilcatton.com. Dates are publication dates. Primary sources for this issue are listed in each article's fact box.
What this issue found · One of two

The ledger

Ten cases graded, and two shown for comparison. The question behind the verdicts, and what each confidence level means, are on page .

Case Status, Sept 2026 What holds it Who carries the cost Verdict · confidence
OPM-MEG brain scanner Research use since 2021; approval hoped 2027 Device approval, then three more approvals Patients who could have been scanned clinically ExplainsHigh
Self-healing concrete On the market; rarely specified Tenders scored on build price Whoever maintains the asset later ExplainsLow
AI reading of brain MRI Validated 2026; not in routine care Four approvals ahead of it Patients far from early adopters Partly explainsLow
AI-discovered lung drug Phase III from July 2026 Trial and approval, deliberately slow People with a named disease Partly explainsModerate
Public consultation Routine A stage no answer moves People with direct experience Runs the other wayLow
Post-quantum migration UK milestones 2028 / 2031 / 2035 An internal decision, deferred Owners of long-lived records Runs the other wayModerate
Data profiles Widespread Nobody's agreement needed The person described Runs the other wayModerate
Small modular reactors First commercial unit behind schedule Engineering and unit economics Whoever funds the subsidy Does not explainModerate
Precision farming Adoption below dealer forecasts for 25 years Designed for the wrong farm Farmers it was not built for Does not explainModerate
Cyber protection for the smallest Deployed; sold by ability to pay Price Sole traders and the self-employed Does not explainHigh
For comparison: cases that reached people
Optical atomic clock Trialled at sea, 2025 One authority; nothing further for a trial Nobody; it moved ComparisonNot graded
Accessibility standards Established; wider benefit documented Permission was imposed Nobody; this one arrived ComparisonNot graded
Fig. 7  Status is sourced in each article's fact box. Verdicts and confidence are the author's judgement. The governance mechanism (page ) is argued, not graded.
2
of 10: the permission chain explains the delay
2
of 10: it partly explains it
3
of 10: permission runs the other way
3
of 10: permission does not explain it at all
Counts describe the cases in this issue, which were chosen by the author (page ). They are not rates in the world.
What this issue found · Two of two

The instrument

Five questions to ask about a technology that is proven and still waiting. The answers fit on one page, and most organisations have never written them down.

01
Has it worked for someone who did not build it?
Start here. Ask for evidence from conditions like service, gathered by someone with nothing riding on the result. If the evidence is thin, the other four questions are premature, and the useful conversation is about the product.
02
How many separate authorities must agree?
Write down the number, then the names. Record the specific decision each one takes, and whether it can be taken independently or waits on another. Four slow approvals and one slow approval need different fixes, and they are usually described in the same words.
03
What is each one protecting?
Name the harm each approval was set up to prevent. If nobody can say, the approval has either outlived its purpose or is not understood by the people running it, and either is worth knowing. Most approvals will turn out to be protecting something real, which keeps the exercise honest.
04
Is the benefit on the form at all?
Look for the value the process cannot record. Savings that arrive after the decision-maker has moved on, land in another organisation's budget, or rest on a long projection tend to score nothing.
05
What does the wait cost, and to whom?
Name who pays; the amount can come later. An exact figure is rarely available. A named party and a rough order of magnitude, written beside the deferral, are enough to make the cost part of the decision.
What it produces

One page

A written account of a chain that already exists. It adds no approval step, board or stage.

The caveat

Untested

Boards have been shown uncomfortable documents before and filed them. Nobody yet knows whether writing the chain down changes what happens next.

If you use it

If you have seen an organisation record the cost of a deferral beside the deferral itself, that is the evidence this argument is missing. Page says how to send it.